Skip to main content
  • Clinical Update

    What Ophthalmologists Need to Know About Migraine

    By Reena Mukamal, Contributing Writer, interviewing Kathleen Digre, MD, Anat Galor, MD, MSPH, and Sean Gratton, MD

    Download PDF

    Although migraine is a neuro­logic illness, it is frequently accompanied by uncomfort­able ophthalmic symptoms, which can cause significant reduction in visual quality of life. What’s more, ocular sur­face diseases can exacerbate headaches in migraine patients, and migraines can also trigger intense symptoms of ocular surface disease. For these reasons, it’s not surprising that ophthalmologists are often the first stop for patients who are experiencing migraine and associat­ed symptoms.

    By understanding the links between migraine and the eyes, ophthalmologists may be better able to support patients with education, treatment, and/or referral to specialists.

    Visual Symptoms Connected to Migraine

    Ocular manifestations of migraine can strike with or without accompanying head pain. Photophobia, visual aura, and eye pain are the most common and bothersome ocular symptoms.

    Photophobia. Extreme light sensi­tivity affects up to 90% of migraine patients, said Kathleen Digre, MD, at Moran Eye Center, University of Utah in Salt Lake City. Although it can be a symptom of other eye conditions, in­cluding ocular surface diseases, chronic photophobia is a diagnostic criterion for migraine, she said.

    Visual aura. About a quarter of mi­graine patients experience visual aura, which can include teichopsia, flashing lights, wavy lines or dots, blind spots, or loss of one or both sides of vision. These disturbances can precede or arrive with headache; they can even occur without a headache.

    Although many ophthalmologists may refer to visual aura as “ocular migraine,” in truth, there is no such thing, said Dr. Digre. “Ocular migraine appears nowhere in the International Classification of Headache Disorders.” Patients—even those who are experi­enced migraineurs—frequently have trouble telling whether the aura affects one eye or both. Dr. Digre explained that this is because aura almost always originates in the brain, not the eyes. (She noted that retinal migraine is a rare migraine type that causes monoc­ular visual loss and has been associated with central retinal artery vasospasm.)

    Pain and ocular surface discom­fort. Pain and pressure behind the eyes can be classic signs of migraine. But dryness, scratchiness, burning, irrita­tion, and tearing can also be signals of migraine—and they can be associated with ocular surface diseases, including dry eye disease, blepharitis, and allergic conjunctivitis. When a comprehensive eye exam does not reveal signs of these disorders and when standard ocular surface disease treatments do not im­prove symptoms, it’s important to look for other causes, such as migraine, said Anat Galor, MD, MSPH, at the Bascom Palmer Eye Institute in Miami. “Abnor­mal nerves underlie many diseases that we have traditionally thought about as ocular surface diseases. The answer is not always on the surface of the eye or visible at the slit lamp,” she said.

    Pain Pathways
    PAIN PATHWAYS. Eye pain and migraine pain use similar pathways involving the trigeminal nerve and autonomic nervous system, both of which can cause eye symptoms.

    Links Between the Eyes and the Brain

    Trigeminal system. The primary mech­anism that links eye pain and migraine pain is the trigeminal system (Fig. 1). The trigeminal nerve innervates the eye, and it has a foundational role in pathophysiology of migraine, said Sean Gratton, MD, at the University of Mis­souri–Kansas City. Dr. Digre added that migraine patients are believed to have a problem with sensory integration, in which “the brain itself is more sensitive to light, sound, odors, pain, touch, and other stimuli. Something may trigger the migraine, and this activates the trigeminal system, which innervates not just the dura and blood vessels in the head causing head pain but also the eye and cornea, which can cause eye pain. That is why the eye can be integral in the migraine mechanism.”  

    Autonomic nervous system. The trigeminal pathway is also integrally re­lated to the autonomic nervous system (ANS), which can also contribute to migraine, according to Drs. Digre and Gratton. “This is why some migraineurs have droopy eyelid, red eyes, tearing, pupillary changes, and other symptoms regulated by the ANS,” Dr. Digre said.

    When Ocular Surface Disease Is Related to Migraine

    Symptoms of ocular surface disease are more common among individuals with migraine than among those who don’t get migraines, according to Dr. Galor. She noted that both individuals with migraine and those with symptoms of ocular surface disease often report ex­acerbation of symptoms with exposure to light. Studies have shown increased corneal sensitivity both in patients with migraine and in those with symptoms of dryness, she said. “Patients with dry eye symptoms are continuously stimulating their trigeminal system,” said Dr. Digre. This can increase the frequency of migraine in those who are susceptible to the condition. Addition­ally, “individuals with migraine are, in general, hypersensitive to all kinds of stimuli, so they may be more likely to experience ocular surface symptoms as severe,” said Dr. Gratton. It can be a vicious cycle, in which one condition continually aggravates the other, he said. The ocular surface disease can stimulate the trigeminal afferents (also known as peripheral sensitization) so much that the nuclei in the brain stem (central sensitization) actually start sig­naling pain when the underlying initial stimulus is gone, said Dr. Digre.

    Ocular surface disease root causes should be identified and treated com­prehensively, Dr. Gratton said.

    Assess neurologic contributors. To help determine whether ocular surface pain and ocular surface disease symptoms exist independently or are related to migraine, Dr. Digre suggests asking patients the following: 1) does the pain interfere with life, 2) is there light sensitivity, and 3) is there nausea or vomiting accompanied by eye pain? If patients answer yes to two of these three questions, migraine or other neurologic contributors should be in­vestigated. “Other tell-tale signs include light sensitivity at examination, prom­inent venous pulsations, and reduced pain with superficial temporal artery compression or superficial supraorbital artery compression,” said Dr. Digre. When nerve contribution is suspected, Dr. Galor puts a drop of proparacaine into each eye and checks for a decrease in pain. Persistence of pain following anesthesia suggests central sensitization or other nonocular surface-related contributors.1

    Migraine Management

    While ophthalmologists may not be equipped to diagnose or prescribe exhaustively for migraine, they can uncover neuropathic connections to eye symptoms, educate patients, and create established referral pathways with providers who offer comprehensive migraine treatment, said Dr. Gratton. He emphasizes a three-part approach to management: “abortive treatments that are taken when a headache starts; preventive therapy to decrease the frequency, intensity, and duration of migraine; and lifestyle changes aimed to reduce migraine triggers.”

    Dr. Galor said, “When I see an individual with eye pain whom I believe has neuropathic mechanisms and shares features with migraine [e.g., photophobia], I use strategies that I borrow from neurologists along with tools I have in my ophthalmology office. I also lean on connections built with neurology and pain specialists in my community.”

    Pain and Symptom Relief

    For acute migraine, Drs. Digre and Gratton recommend several treatments, including timolol eye drops (see “Can Glaucoma Drops Help Migraine?”).

    Treat the pain. For acute pain relief, Drs. Digre and Gratton start with over-the-counter medicines includ­ing acetaminophen/paracetamol and ibuprofen.

    Triptans are an often-prescribed family of treatments; “they are tried and true with a long track record of safety,” Dr. Gratton said. They can, however, cause blood vessels to con­strict and are not recommended for people with heart conditions. Lasmid­itan (Reyvow) is an alternative for patients who may be at risk of stroke or heart attack, according to Dr. Gratton.

    Gepants are a newer class of medicines that work by blocking the receptor for calcitonin gene-related peptide (CGRP), a pain signal–carrying protein released during migraine. These treatments, which include rimegep­ant (Nurtec ODT) and ubrogepant (Ubrelvy) are more expensive and may not be covered by insurance as a first-line treatment, cautioned Dr. Digre.

    Offer FL-41 lenses. Patients who struggle with photophobia can benefit from FL-41 lenses. These rose-tinted glasses developed in the 1980s can help alleviate light sensitivity by blocking out wavelengths of light known to exacerbate migraine and photophobia. “The FL-41 lens is my favorite device, and it is backed by research,” said Dr. Digre. Dr. Galor agrees that FL-41 lenses are a go-to tool for any patient with photophobia.

    “They can be especially helpful for people who have chronic photophobia that persists in between migraines,” said Dr. Gratton.

    Can Glaucoma Drops Help Migraine?

    Although oral beta blockers are commonly used for migraine prevention, they have not been useful in the treatment of acute pain, likely due to their slow absorption.1 But in drop form, the beta blocker timolol may be an effective abortive treatment for migraines.

    In a randomized, placebo-controlled study, researchers evaluated a total of 619 migraine attacks in 50 patients at the Chaithanya Eye Hospital and Research Institute in Trivandrum, India. The patients were treated either with one drop of timolol 0.5% applied in each eye or a placebo drop. At 20 minutes after installation, 82% of patients treated with timolol reported a reduction in pain score by 4 points, compared with 14% in the placebo group.2 For a signif­icant number of patients (42%), timolol eyedrops were administered again 10 minutes after the first installation.

    The efficacy of the drop in relieving pain is likely due to how quickly it can achieve therapeutic concentrations in the blood; blinking vigorously upon drop application may facilitate passage into the lacrimal drainage duct.3 The drops are inexpensive, widely available, and very well tolerated, according to Dr. Gratton. “I have found them to be effective in a subset of patients who take them as needed,” he said. Dr. Digre finds them to be a good acute treat­ment “as long as the patient doesn’t have asthma.”


    1 Katz B. JAMA Ophthalmology. 2020;138(11):1166-1167.

    2 Kurian A et al. JAMA Ophthalmology. 2020;138(11):1160-1166.

    3 Migliazzo C et al. Missouri Medicine. 2014;111(4):283-288.


    “If the patient is taking abortive drugs more than twice a week, I suggest finding a preventive treatment,” said Dr. Gratton.

    Traditional medications. When it comes to reducing migraine recurrence, traditional prophylactic medications are the starting point for many patients. These drug families were originally designed to treat other conditions and later discovered to also prevent or reduce the frequency of migraines. Antiepi­leptic drugs (e.g., topiramate), beta blockers (e.g., propranolol), and anti­depressants (e.g., amitriptyline) may be prescribed as a first step because they are generally covered by most insurance, said Dr Digre. “The process of finding the right preventive medica­tion can involve a lot of trial and error, and some side effects are likely to be generated with all of these drugs,” said Dr. Gratton.

    CGRP monoclonal antibodies. Designed to prevent and alleviate migraine, CGRP monoclonal anti­bodies work by blocking release of the neurotransmitter CGRP or neutralizing it in order to prevent headaches.2 The drug is delivered through injection (self-administered) or infusion (at the doctor’s office) monthly or quarterly. “There are now four FDA-approved options—eptinezumab (Vyepti), erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality)—and they are extremely well-tolerated and effective,” said Dr. Gratton. “These drugs are game-changers for patients with migraine, and they have few side effects. But they are very expensive [approximately $600 per month] and not covered by many insurance payers as a first line of treatment,” said Dr. Digre, adding that some payers require prior authorization. Dr. Galor is less enthusiastic about these medicines. “In my experience, they are solidly medi­ocre when it comes to addressing eye pain with neuropathic contributors,” she said.

    OnabotulinumtoxinA. OnabotulinumtoxinA is an FDA-approved preventive treatment for chronic migraine. By inhibiting the release of acetylcholine—another neurotransmitter involved in the trigeminal pain pathway—in­jections every 12 weeks can reduce the frequency of headaches.2 Botox is one of several preparations. “On­abotulinum toxin is already being used in many ophthalmology offices for various oculoplastic issues, including blepharospasm and hemifacial spasm,” said Dr. Galor. Dr. Gratton said, “It’s a good option for people who have very frequent migraine. It’s especially good for patients who take many other medicines because it’s noninteractive.” He added that several small studies have shown that onabotulinumtoxinA also has the potential to help with dry eye symptoms and photophobia. The cost of this treatment is comparable to that of CGRP monoclonal antibodies, and insurance coverage varies and often requires prior authorization.

    Neuromodulation devices. These devices use electrical currents or magnets to adjust or change activity of the nerve pathways involved in a migraine.3 They can be applied acutely to stop headaches that are already underway, and they are increasingly being used for prevention, according to Dr. Gratton. Neuromodulation, which offers a drug-free alternative for patients who have tolerability issues with pharmaco­logical medications, carries no systemic side effects, he said. Treatments can be self-administered daily at home.

    There are currently four FDA-approved devices on the market targeting different nerves: Cefaly Dual Enhanced (Cephaly), gammaCore (electroCore), Nerivio (Theranica), and SpringTMS (eNeura). One device—Cefaly—is available for purchase without a prescription. “Nerve mod­ulation can take two to three months before you get a preventative effect. Patients have to buy in and stick with the treatment,” said Dr. Galor. “These noninvasive devices make sense for patients who take a lot of medications, but they can cost hundreds of dollars, and not all of them offer a money-back guarantee,” said Dr. Gratton.

    Lifestyle Changes

    Manage triggers. Dr. Digre empha­sized the importance of asking patients about migraine risk factors, including family history, stress, depression, and sleep apnea, and talking about obesi­ty4 when necessary. “Education about lifestyle management is free and easy and can make a world of difference to patients,” she said. Dr. Gratton informs patients that both the frequency and the intensity of migraine is influenced by factors that the patient has some control over. “Stress is a big influencer. Others include poor sleep, poor hydra­tion, inconsistent nutrition/skipping meals, and not exercising,” he said. He also tells patients that overuse of acute medications can lead to medica­tion-overuse headache. Both Dr. Digre and Dr. Gratton often recommend supplementing with magnesium oxide and riboflavin (vitamin B2), which they say have minimal risks and have been found effective as preventive strategies.


    1 Baksh B. et al. Eye Brain. 2021;13:41-57.

    2 Siddiqui M. et al. Cureus. 2021;13(1):e13002.

    3 Ailani J. et al. Headache. 2021;61(7):1021-1039.

    4 Martami F. et al. Headache. Published online July 19, 2022.


    Dr. Digre is professor of neurology and ophthal­mology at the John A. Moran Eye Center, Univer­sity of Utah in Salt Lake City. Relevant financial disclosures: None.

    Dr. Galor is a staff physician at the Miami Veterans Affairs Medical Center and professor of ophthalmology at Bascom Palmer Eye Institute, University of Miami, Florida. Relevant financial disclosures: None.

    Dr. Gratton is associate professor of neurolo­gy and ophthalmology at the University of Mis­souri-Kansas City School of Medicine. Relevant financial disclosures: None.

    For full disclosures and the disclosure key, see below.

    Full Financial Disclosures

    Dr. Digre Elsevier: P; part owner on a patent pending thin-filmed technology: P; Springer: P.

    Dr. Galor Allergan: C; AstraZeneca: C; Dompé: C; Novaliq: C; Novartis: C; Oculus: C; Oyster Point: C; Shire: C; Tarsus: C.

    Dr. Gratton None.

    Disclosure Category



    Consultant/Advisor C Consultant fee, paid advisory boards, or fees for attending a meeting.
    Employee E Hired to work for compensation or received a W2 from a company.
    Employee, executive role EE Hired to work in an executive role for compensation or received a W2 from a company.
    Owner of company EO Ownership or controlling interest in a company, other than stock.
    Independent contractor I Contracted work, including contracted research.
    Lecture fees/Speakers bureau L Lecture fees or honoraria, travel fees or reimbursements when speaking at the invitation of a commercial company.
    Patents/Royalty P Beneficiary of patents and/or royalties for intellectual property.
    Equity/Stock/Stock options holder, private corporation PS Equity ownership, stock and/or stock options in privately owned firms, excluding mutual funds.
    Grant support S Grant support or other financial support from all sources, including research support from government agencies (e.g., NIH), foundations, device manufacturers, and\or pharmaceutical companies. Research funding should be disclosed by the principal or named investigator even if your institution receives the grant and manages the funds.
    Stock options, public or private corporation SO Stock options in a public or private company.
    Equity/Stock holder, public corporation US Equity ownership or stock in publicly traded firms, excluding mutual funds (listed on the stock exchange).